Metabolic and cardiovascular consequences of polycystic ovary syndrome

Minerva Ginecologica

Volumn 60, Issue 1, 2008, Pages 39-51

  Orio, F ^a,b   Vuolo, L ^b   Palomba, S ^c   Lombardi, G ^b   Colao, A ^b  

^a UNIVERSITY OF NAPLES PARTHENOPE   (Italy)

^b UNIVERSITY OF NAPLES FEDERICO II   (Italy)

^c UNIVERSITY MAGNA GRAECIA OF CATANZARO   (Italy)

Author keywords

Cardiovascular diseases; Metabolic diseases; Polycystic ovary syndrome

Indexed keywords

ABDOMINAL OBESITY; ANOVULATION; CARDIOPULMONARY INSUFFICIENCY; CARDIOVASCULAR DISEASE; DYSLIPIDEMIA; ELECTROCARDIOGRAM; ENDOTHELIAL DYSFUNCTION; HUMAN; HYPERANDROGENISM; HYPERTENSION; IMPAIRED GLUCOSE TOLERANCE; INFERTILITY; INSULIN RESISTANCE; METABOLIC DISORDER; OVARY POLYCYSTIC DISEASE; REVIEW;

ADULT; CARDIOVASCULAR DISEASES; CORONARY DISEASE; DIABETES MELLITUS, TYPE 1; DIABETES MELLITUS, TYPE 2; DYSLIPIDEMIAS; ELECTROCARDIOGRAPHY; FEMALE; GLUCOSE INTOLERANCE; HUMANS; INCIDENCE; METABOLIC DISEASES; MIDDLE AGED; OBESITY; POLYCYSTIC OVARY SYNDROME; RISK FACTORS;

EID: 42049111646     PISSN: 00264784     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (94)

1. Norman JR, Dewailly D, Legro SR, Hickey ET. Polycystic ovary syndrome. Lancet 2007;370:685-97.
2. Azziz R. Controversy in clinical endocrinology: diagnosis of polycystic ovarian syndrome: the Rotterdam criteria are premature. J Clin Endocrinol Metab 2006;91:781-5.
3. Azziz R, Carolina E, Dewailly D, Diamanti-Kandarakis E, Escobar-Morreale HF, Futterweit W. Positions statement: criteria for defining polycystic ovary syndrome as a predominantly hyperandrogenic syndrome: an Androgen Excess Society guideline. J Clin Endocrinol Metab 2006;91:4237-45.
4. Rotterdam ESHRE/ASRM-Sponsored PCOS Consensus Workshop Group. Revised 2003 yndrome. Fertil Steril 2004;81:19-25.
5. Lorenz LB, Wild RA. Polycystic ovarian syndrome: an evidence-based approach to evaluation and management of diabetes and cardiovascular risks for today's clinician. Clin Obstet Gynecol 2007;50:226-43.
6. Orio F, Palomba S, Colao A. Cardiovascular risk in women with polycystic ovary syndrome. Fertil Steril 2006;86(Suppl 1):S20-1.
7. Cussons AJ, Stuckey BG, Watts GF. Cardiovascular disease in the polycystic ovary syndrome: new insights and perspectives. Atherosclerosis 2006;185:227-39.
8. Glueck CJ, Papanna R, Wang P, Goldenberg N, Sieve-Smith L. Incidence and treatment of metabolic syndrome in newly referred women with confirmed polycystic ovarian syndrome. Metabolism 2003;52:908-15.
9. National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High blood Cholesterol in Adults (Adult Treatment Panel III). Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High blood Cholesterol in Adults (Adult Treatment Panel III):final report. Circulation 2002;106:3143-421
10. Sam S, Dunaif A. Polycystic ovary syndrome: syndrome XX? Trends Endocrinol Metab 2003;14:365-70.
11. Reaven G. Metabolic Syndrome: pathophysiology and implications for management of cardiovascular disease. Circulation 2002;106:286-8.
12. Ferrannini E, Natali A, Bell P, Cavallo-Perin P, Lalic N, Mingrone G. Insulin Resistance and hypersecretion in obesity. European Group for the Study of Insulin Resistance (EGIR). J Clin Invest 1997;100:1166-73.
13. Dunaif A. Insulin resistance and the polycystic ovary syndrome: mechanism of action and implications for pathogenesis. Endocr Review 1997;18:774-80.
14. Mather KKJ, Kwan F, Corenblum B. Hyperinsulinemia in polycystic ovary syndrome correlates with increased cardiovascular risk independent of obesity. Fertil Steril 2000;73:150-6.
15. Diamanti-Kandarakis E, Papavassiliou AG. Molecular mechanism of insulin resistance in polycystic ovary syndrome. Trends Mol Med 2006;12:324-32.
16. Robinson S, Kiddy D, Gelding SV. The relationship of insulin insensitivity to menstrual pattern in women with hyperandrogenism and polycystic ovaries. Clin Endocrinol 1993;39:351-5.
17. Toprak S, Yonem A, Cakir B. Insulin Resistance in nonobese patients with polycystic ovary Syndrome 2001 Horm Res 55:65-70.
18. Carmina E, Bucchieri S, Esposito A, Del Puente A, Mansueto P, Orio F et al. Abdominal fat quantity and distribution in women with polycystic ovary syndrome and extent of its relation to insulin resistance. J Clin Endocrinol Metab 2007;92:2500-5.
19. Dunaif A, Xia J, Book CB, Schenker E, Tang Z. Excessive insulin receptor serine phosphorylation in cultured fibroblasts and in skeletal muscle. A potential mechanism for insulin resistance in the polycystic ovary syndrome. J Clin Invest 1995;96:801-10.
20. Ehrmann DA, Barnes RB, Rosenfield RL, Cavaghan MK, Imperial J. Prevalence of impaired glucose tolerance and diabetes in women with polycystic ovary syndrome. Diabetes Care 1999;22:141-6.
21. Legro RS, Kunselman AR, Dodson WC, Dunaif A. Prevalence and predictors of risk for type 2 diabetes mellitus and impaired glucose tolerance in polycystic ovary syndrome: a prospective, controlled study in 254 affected woman. J Clin Endocrin Metab 1999;84:165-9.
22. Polonsky KS, Sturis J, Bell GI. Non insulin dependent diabetes mellitus-a genetically programmed failure of the beta cell to compensate for insulin resistance. N Engl J Med 1996;334:377-83.
23. Ehrmann DA, Breda E, Corcoran MC. Impaired beta cell compensation to dexamethasone induced hyperglicemia in women with polycystic ovary syndrome. Am J Physiol Endocr Metab 2004;287:E241-E246.
24. Dunaif A, Finegood DT. Beta cell dysfunction independent of obesity and glucose intolerance in the polycystic ovary syndrome. J Clin Endocrin Metab 1996;81:942-7.
25. Gambineri A, Pelusi C, Manicardi E. Glucose intolerance in a large cohort of Mediterranean women with polycystic ovary sindrome: phenotype and associated factors. Diabetes 2004;53:2353-8.
26. Kousta E, Cela E, Lawrence NJ. The prevalence of polycystic ovaries in women with a history of gestational diabetes. Clin Endocrinol 2000;53:501-7.
27. Heiat A. Impact of age on defition of standards for ideal weight. Prev Cardiol 2003;6:104-7.
28. Azziz R, Ehrmann D, Legro RS. Troglitazone improves ovulation and hirsutism in the Polycystic ovary syndrome: a multicenter, double blind, placebo controlled trial. J Clin Endocr Metab 2001;86:1626-32.
29. Carmina E, Legro Rs, Stamets K, Lowell J, Lobo Ra. Difference in body weight between American and Italian women with polycystic ovary sindrome: influence of the diet. Hum Reprod 2003;18:2289-93.
30. Knochenhauer ES, Key TJ, Kahsar-Miller M, Waggoner W, Boots LR, Azziz R. Prevalence of the polycystic ovary syndrome in unselected black and white women of the southeastern United States: a prospective study. J Clin Endocr Metab 1998;83:3078-82.
31. Diamanti-Kandarakis E, Kouli CR, Bergiele AT. A survey of the polycystic ovary syndrome in the Greek island of Lesbos: hormonal and metabolic profile. J Clin Endocrinol Metab 1999;84:4006-11.
32. Asuncion M, Calvo RM, san MillanJL, Sancho J, Avila S, Escobar-Morreale HF. A prospective study of the prevalence of the polycystic ovary syndrome in unselected Caucasian women from Spain. J Clin Endocrinol Metab 2000;85:2434-8.
33. Cascella T, Palomba S, De sio I, Manguso F, Giallauria F, De Simone B. Visceral fat is associated with cardiovascular risk in women with polycystic ovary syndrome. Hum Reprod 2008 ;23:153-9.
34. Cascella T, Giallauria F, Tafuri D, Lombardi G, Colao A, Vigorito C et al. Cardiovascular complication of obesity. Monaldi Arch Chest Dis 2006;66:270-4.
35. Haffner SM. Abdominal adiposity and cardiometabolic risk: do we have all the answers? Am J Med 2007;120:S10-6.
36. Marchesini G, Brizi M, Bianchi G. Nonalcoholic fatty liver disease: a feature of the metabolic syndrome Diabetes. 2001;50:1844-50.
37. Steven M. Haffner. Relationship of metabolic risk factors and development of cardiovascular disease and diabetes. Obesity2006;14:121S-127S.
38. Wang JX, Davies MJ, Norman RJ. Polycystic ovarian syndrome and the risk of spontaneous abortion following assisted reproductive technology treatment. Hum Reprod 2001;16:2606-9.
39. Pirwany IR, Fleming R, Greer IA, Packard CJ, Sattar N. Lipids and lipoprotein subfractions in women with PCOS: relationship to metabolic and endocrine parameters. Clin Endocrinol 2001;54:447-53.
40. Bass KM, Newschaffer CJ, Klag MJ, Bush TL. Plasma lipoprotein levels as predictors of cardiovascular death in women. Arch Intern Med 1993;153:2209-16.
41. Legro RS, Kunselman AR, Dunaif A. Prevalence and predictors of dyslipidemia in women with polycystic ovary syndrome. Am J Med 2001;111:607-13.
42. Talbott E, Clerici A, Berga SL, Kuller L, Guzick D, Detre K et al. Adverse lipid and coronary heart disease risk profiles in young women with polycystic ovary syndrome: results of a case-control study. J ClinEpidemiol 1998;51:415-22.
43. Haffner SM, D'Agostino R Jr, Festa A, Bergman RN, Mikkänen L, Karter A et al. Low insulin sensitivity (Si=0) in diabetic and nondiabetic subjects in the insulin resistance atherosclerosis study. Is it associated with components of the metabolic syndrome and nontraditional risk factors? Diabetes Care 2003;26:2796-803.
44. Cameron AJ, Shaw JE, Zimmet PZ. The metabolic syndrome: prevalence in worldwide populations. Endocrinol Metab Clin N Am 2004;33:351-75.
45. Essah PA, Nestler JE. Metabolic syndrome in women with polycystic ovary syndrome. Fertil Steril 2006;86:S18-9.
46. Pierpoint T, McKeigue PM, Isaacs AJ, Wild SH, Jacobs HS. Mortality of women with polycystic ovary syndrome at long-term follow-up. J Clin Epidemiol 1998;51:581-6.
47. Wild S, Pierpoint T, McKeigue P, Jacobs H. Cardiovascular disease in women with polycystic ovary syndrome at long-term follow-up: a retrospective cohort study. Clin Endocrinol 2000;52:595-600.
48. Dahlgren E, Janson PO, Johansson S, Lapidus L, Oden A. Polycystic ovary syndrome and risk for myocardial infarction. Evaluated from a risk factor model based on a prospective population study of women. Acta Obstet Gynecol Scand 1992;71:599-604.
49. Cibula D, Cifkova R, Fanta M, Poledne R, Zivny J, Skibova J. Increased risk of non-insulin dependent diabetes mellitus, arterial hypertension and coronary artery disease in perimenopausal women with a history of the polycystic ovary syndrome. Hum Reprod 2000;15:785-9.
50. Talbott E, Guzick DS, Sutton-Tyrrell K, McHugh-Pemu KP, Zborowski JV, Remsberg KE et al. Evidence for association between polycystic ovary syndrome and premature carotid atherosclerosis in middle-aged women. Arterioscler Thromb Vasc Biol 2000;20:2414-21.
51. Christian RC, Dumesic A, Behhrebeck T, Oberg AL, Sheedy PF, Fitzpatrick LA. Prevalence and predictors of coronary artery disease calcification in women with polycystic ovary syndrome. J Clin Endocr Metab 2003;88:2562-8.
52. Shroff R, Kirshner A, Maifeld M, Van Beek EJR, Jagasia Dinesh, Dokras A. Young obese women with Polycystic ovary syndrome have evidence of early coronary atherosclerosis. J Clin Endocr Metab 2007;92:4609-14.
53. Zawadzki JK, Dunaif A. Diagnostic criteria for polycystic ovary sindrome: towards a rational approach. Boston, MA: Blackwell Scientific; 1992. p. 377-84.
54. Jayagopal V, Kilpatrick ES, Jennings PE, Hepburn DA, Atkin SL. The biological variation of testosterone and sex hormone binding globulin (SHBG) in polycystic ovarian syndrome. Fertil Steril 2004;81:19-25
55. Harjai KJ Potential new cardiovascular risk factors: left ventricular hypertrophy, homocysteine, lipoprotein(a), triglycerides, oxidative stress, and fibrinogen. Ann Intern Med 1999;131:376-86.
56. Zimmermann S, Phillips RA, Dunaif A, Finegood DT, Wilkenfeld C, Ardeljan M et al. Polycystic ovary syndrome: lack of hypertension despite profound insulin resistance. J Clin Endocrinol Metab 1992;75:508-13.
57. Holte J, Pennarelli G, Berne C, Bergh T, Lithell H. Elevated ambulatory day-time blood pressure in women with polycystic ovary syndrome: a sign of a pre-hypertensive state? Hum Reprod 1996;11:23-8.
58. Elting MW, Korsen TJM, Bezemer PD, Schoemaker J. Prevalence of diabetes mellitus, hypertension and cardiac complaints in a follow-up study of a Dutch PCOS population. Hum Reprod 2001;16:556-60
59. Glueck CJ, Papanna R, Wang P, Goldenberg N, Sieve Smith L. Incidence and treatment of metabolic syndrome in newly referred women with confirmed polycystic ovarian syndrome. Metabolism 2003;52:908-15.
60. Orio jr, Palomba S, Spinelli L, Cascella T, Tauchmanovà L, Zullo F. The cardiovascular risk of young women with Polycystic Ovary sindrome:an observational, analytical, prospective case-control study. J Clin Endocrinol Metab 2004;89:3696-701.
61. Vaccaro O, Cardoni O, Cuomo V, Panarelli W, Laurenzi M, Mancini M et al. Relationship between plasma insulin and left ventricular mass in normotensive participants of the Gubbio study. Clin Endocrinol 2003; 58:316-22.
62. De Simone G, Devereux RB, Roman MJ, Halderman MH, Laragh JH. Relation of obesity and gender to left ventricular hypertrophy in normotensive adults. Hypertension 1994; 23:600- 6.
63. De Simone G, Daniels SR, Devereux RB, Meyer RA, de Divitiis O. Left ventricular mass and body size in normotensive children and adults: assessment of allometric relations and impact of overweight. J Am Coll Cardiol 1992;20:1251-60.
64. Tiras MB, Yalcin R, Noyan V, Maral I, Yildirim M, Dortlemez O et al. Alterations in cardiac flow parameters in patients with polycystic ovarian syndrome. Hum Reprod 1999; 14:1949-52.
65. Yarali H, Yildirir A, Aybar F, Kabakci G, Bukulmez O, Akgul E et al. Diastolic dysfunction and increased serum homocysteine concentrations may contribute to increased cardiovascular risk in patients with polycystic ovary syndrome. Fertil Steril 2001;76:511-6.
66. Lerman A, Edwards BS, Hallett JW, Heublein DM, Sondberg SM, Burnett Jr JC. Circulating and tissue endothelin immunoreactivity in advanced atherosclerosis. N Engl J Med 1991; 325:997-1001
67. Ferri C, Pittoni V, Piccoli A, Laurenti O, Cassone MR, Bellini C. Insulin stimulates endothelin-1 secretion from human endothelial cells and modulates its circulating levels in vivo. J Clin Endocr Metab 1995;80:829-35.
68. Orio F Jr, Palomba S, Cascella T, De Simone B, Di Biase S, Russo T et al. Early impairment of endothelial structure and function in young normal-weight women with polycystic ovary syndrome. J Clin Endocrinol Metab 2004;89: 4588-93.
69. Diamanti-Kandarakis E, Spina G, Kouli C, Migdalis I. Increased endothelin-1 levels in women with polycystic ovary syndrome and the beneficial effect of metformin therapy. J Clin Endocrinol Metab 2001;86:4666-73.
70. Paradisi G, Steinberg HO, HempfingA, Cronin C, Hook G, Shepard MK. Polycystic ovary syndrome is associated with endothelial dysfunction. Circulation 2001;103:1410-5.
71. Ki-Jarvinen H. Insulin resistance and endothelial dysfunction, Best Practice Res Clin Endocrin Metab 2003;17:411-30.
72. Orio F Jr, Palomba S, Cascella T, De Simone B, Manguso F, Savastano S. Improvement in Endothelial structure and function after metformin treatment in young normal weight women with polycystic ovary syndrome: Results of a six month study. J Clin Endocr Metab 2005;90:6072-6.
73. Orio F Jr, Palomba S, Cascella T, Di Biase S, Manguso F, Tauchmanovà L. The increase of leukocytes as a new putative marker of low grade chronic inflammation and early cardiovascular risk in polycystic ovary syndrome. J Clin Endocr Metab 2005;90:2-5
74. Ibanez L, Jaramillo AM, Ferrer A, de Zegher F. High neutrophil count in girls and women with hyperinsulinaemic hyperandrogenism: normalization with metformin and flutamide overcomes the aggravation by oral contraception. Hum Reprod 2005;20:2457-62.
75. Kelly CC, Lyall H, Petrie JR, Gould GW, Connell JM, Sattar N. Low grade chronic inflammation in women with polycystic ovarian syndrome. J Clin Endocrinol Metab 2001; 86:2453-5.
76. Hoffman M, Blum A, Baruch R, Kaplan E, Benjamin M. Leukocytes and coronary artery disease. Atherosclerosis 2004;172:1-6.
77. Hasegawa T, Negishi T, Deguchi M. WBC count, atherosclerosis and coronary risk factors. J Atheroscler Thromb 2002;9:219-23.
78. Pannacciulli N, Giorgino F, Martina RA, Resta O, Giorgino F, De Pergola G. Effect of family history of type 2 diabetes on white blood cell count in adult women. Obes Res 2003;11:1232-7.
79. Verma S, Buchanan MR, Anderson TJ. Endothelial function testing as a biomarker of vascular disease. Circulation 2003;108:2054-9.
80. Freeman DJ, Norrie J, Caslake MJ, Gaw A, Ford I, Lowe GD et al. C- reactive protein is an independent predictor of risk for the development of diabetes in the West of Scotland Coronary Prevention Study. Diabetes 2002;51:1596-600.
81. Festa A, D'Agostino R Jr, Howard G, Mykkanen L, Tracy RP, Haffner SM. Chronic subclinical inflammation as part of the insulin resistance syndrome: the Insulin Resistance Atherosclerosis Study (IRAS). Circulation 2000;102:42-7.
82. Folsom AR, Pankow JS, Tracy RP, Arnett DK, Peacock JM, Hong Y et al. Investigators of the NHBLI Family Heart Study. Association of C-reactive protein with markers of prevalent atherosclerotic disease. Am J Cardiol 2001;88:112-7.
83. Meade TW, Cooper JA, Chakrabarti R, Miller GJ, Stirling Y, Howarth DJ. Fibrinolityc activity and clotting factor in ischaemic heart disease in women. Br Med J 1996;312:1581.
84. Orio F Jr, Palomba S, Cascella T, Tauchmanova L, Nardo LG, Di Biase S et al. Is plasminogen activator inhibitor-1 (PAI-1) a cardiovascular risk factor in young women with polycystic ovary syndrome? RBM Online 2004;9:505-10.
85. Rocha S, Stier Jr CT. Pathophysiological effects of aldosterone in cardiovascular tissues. Trends Endocrinol Metab 2001;7:308-14.
86. th anniversary of aldosterone. J Clin Endocr Metab 2003; 88:2364-72.
87. Romagni P, Rossi F, Guerrini L, Quirini C, Santiemma V. Aldosterone induces contraction of the resistance arteries in man. Atherosclerosis 2003;166:345-9.
88. Cascella T, Palomba S, Tauchmanovà L, Manguso F, Di Biase S, Labella D. Serum aldosterone concentration and cardiovascular risk in women with Polycystic Ovarian Syndrome. J Clin Endocr Metab 2006;91:4395-400.
89. DeUgarte CM, Bartolucci AA, Azziz R. Prevalence of insulin resistance in the polycystic ovary syndrome using the homeostasis model assessment. Fertil Steril 2005;83:1454-60.
90. Orio F, Giallauria F, Palomba S, Cascella T, Manguso F, Vuolo L. Cardiopulmonary impairment in young women with Polycystic Ovarian Syndrome. J Clin Endocr Metab 2006; 91:2967-71.
91. Myers J, Prakash M, Froelicher V, Do D, Partington S, Atwood JE. Exercise capacity and mortality among men referred for exercise testing. New Engl J Med 2002;346:793-801.
92. Kavanagh T, Mertens DJ, Hamm LF, Beyene J, Kennedy J, Corey P. Peak oxygen intake and cardiac mortality in womwn referred for cardiac rehabilitation. J Am Coll Cardiol 2003;42:2139-43.
93. Vigorito C, Giallauria F, Palomba S, Cascella T, Manguso F, Lucci R. Beneficial effect of a three month structured exercise training program on cardiopulmonary functional capacity in young women with polycystic ovary syndrome. J Clin Endocr Metab 2007;92:1379-84.
94. Orio F, Palomba S, Cascella T, Manguso F, Vuolo L, Tafuri D. Lack of electrocardiographic changes in women with Polycystic Ovary Syndrome. Clin Endocrinol 2007;67:46-50.